Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Oral Glutathione Supplementation on the Levels of Blood Glutathione
Effect of Oral Glutathione Supplementation on the Levels of Blood Glutathione and Markers of Oxidative Stress in Healthy Adults (Glutathione Supplementation and Health (GSH) Study)
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Oral Glutathione Supplementation on the Levels of Blood Glutathione
Effect of Oral Glutathione Supplementation on the Levels of Blood Glutathione and Markers of Oxidative Stress in Healthy Adults (Glutathione Supplementation and Health (GSH) Study)
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Aldosterone and the Metabolic Syndrome
Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Aldosterone and the Metabolic Syndrome
Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
Modulation of Biomarkers and Gene Expression by Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects.
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
Modulation of Biomarkers and Gene Expression by Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects.
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Rituximab to Prevent Recurrence of Proteinuria
The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Rituximab to Prevent Recurrence of Proteinuria
The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated:  12/31/1969
Lady Cilento Children's Hospital
mi
from
South Brisbane,
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Lady Cilento Children's Hospital
mi
from
South Brisbane,
Click here to add this to my saved trials
Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes
Exercise Training, CACs, and Vascular Function in Older Veterans With IGT (Impaired Glucose Tolerance)
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center
mi
from
Baltimore, MD
Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes
Exercise Training, CACs, and Vascular Function in Older Veterans With IGT (Impaired Glucose Tolerance)
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Paradise Valley, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lakewood, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lakewood, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Upland, CA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Danbury, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Farmington, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norwich, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norwich, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Trumbull, CT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Doral, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lake Mary, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lake Mary, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange Park, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tamarac, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials